Fate Therapeutics (NASDAQ: FATE) announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE